Drugs / IMPT-514
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06462144 | Jun 2024 → Oct 2025 | anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, systemic lupus erythematosus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06153095 | Feb 2024 → Jan 2025 | lupus nephritis, systemic lupus erythematosus | Lyell Immunopharma, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMPT-514 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06153095 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy” NCT06153095 ↗ |
| Route | Intravenous | “administered intravenously” NCT06153095 ↗ |
| Target | CD19 | “anti-CD19/CD20 CAR T therapy” NCT06462144 ↗ |